



Michael A. Nauck

Ruhr-University Bochum, Germany

• Education

Period	Affiliation	Position
- 1975-1980	University Freiburg	M.S
- 1973-1975	Heinrich Heine University Düsseldorf	M.S

• Affiliations / Experience

Period	Affiliation	Position
- 2015-Present	Head of Clinical Research, Ruhr-University Bochum, St. Josef-Hospital	Research Position
- 2000-2015	Diabetes Centre Bad Lauterberg	Head Physician
- 1993-2000	Ruhr-University Bochum, Knappschafts-Krankenhaus	Consultant
- 1981-1993	University Göttingen, Gastroenterology and Endocrinology	Physician in Training
- 1980-1981	University Göttingen, Biochemistry	Scientist

• Committee Memberships

- ADA/EASD Guideline Writing Group
- Working Group (ADA/EASD/Diabetes UK/ Endocrine Society) Diabetes Remission

• Publications

- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet*. 368:1696-705
- Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. *Diabetologia*. 29:46-54
- Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J Clin Invest*. 91(1):301-7
- Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. *Diabetologia*. 36(8):741-4
- Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. *Diabetologia*